Literature DB >> 24412606

Collagen proportionate area is superior to other histological methods for sub-classifying cirrhosis and determining prognosis.

Emmanuel Tsochatzis1, Sara Bruno2, Graziella Isgro1, Andrew Hall2, Eleni Theocharidou1, Pinelopi Manousou2, Amar P Dhillon2, Andrew K Burroughs3, Tu Vinh Luong4.   

Abstract

BACKGROUND & AIMS: One-year survival in cirrhosis ranges from 1 to 57% depending on the clinical stage. Accurate sub-classification has important prognostic implications but there is no stage beyond cirrhosis using current qualitative histological systems. We compared the performance of all histological semi-quantitative and quantitative methods specifically developed for sub-classifying cirrhosis that have been described to date, with collagen proportionate area (CPA), to evaluate how well they distinguish patients with and without hepatic clinical decompensation at presentation, and in predicting future decompensating events.
METHODS: We included consecutive patients with a histological diagnosis of cirrhosis that had a suitable liver biopsy between 2003 and 2007. We used semi-quantitative histological scoring systems proposed by Laennec, Kumar, and Nagula. We also measured quantitatively nodule size, septal width and fibrous tissue expressed in CPA.
RESULTS: Sixty-nine patients, mean age 52.3±11years, mean MELD 11.8±5.8, median follow-up 56months. Main aetiologies were alcohol (38%) and hepatitis C (27.5%). Twenty-four patients (34.8%) had had a previous episode of clinical decompensation. Amongst the 45 patients who were compensated, 11 (24%) decompensated on follow-up. In Cox regression, amongst all histological parameters, CPA was the only variable independently associated with clinical decompensation up to the time of biopsy, with an odds ratio that ranged from 1.245 to 1.292. Furthermore, only CPA was significantly associated with future decompensation (OR: 1.117, 95% CI 1.020-1.223; p=0.017).
CONCLUSIONS: Cirrhosis can be accurately sub-classified using quantification of fibrosis with CPA, and furthermore CPA is the only independent predictor of clinical decompensation amongst all other histological sub-classification systems described to date.
Copyright © 2014 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24412606     DOI: 10.1016/j.jhep.2013.12.023

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  34 in total

Review 1.  Evolution of the liver biopsy and its future.

Authors:  Dhanpat Jain; Richard Torres; Romulo Celli; Jeremy Koelmel; Georgia Charkoftaki; Vasilis Vasiliou
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 2.  Evaluation of hepatic fibrosis: a review from the society of abdominal radiology disease focus panel.

Authors:  Jeanne M Horowitz; Sudhakar K Venkatesh; Richard L Ehman; Kartik Jhaveri; Patrick Kamath; Michael A Ohliger; Anthony E Samir; Alvin C Silva; Bachir Taouli; Michael S Torbenson; Michael L Wells; Benjamin Yeh; Frank H Miller
Journal:  Abdom Radiol (NY)       Date:  2017-08

Review 3.  Pathobiology of liver fibrosis: a translational success story.

Authors:  Youngmin A Lee; Michael C Wallace; Scott L Friedman
Journal:  Gut       Date:  2015-02-13       Impact factor: 23.059

Review 4.  Virtual touch quantification (VTq) elastography for non-invasive assessment of liver disease and its complications: what the clinician needs to know.

Authors:  David Sherman; Phillip Lung; Philip Shorvon
Journal:  Frontline Gastroenterol       Date:  2016-10-12

5.  Advanced MRI of Liver Fibrosis and Treatment Response in a Rat Model of Nonalcoholic Steatohepatitis.

Authors:  Iris Y Zhou; Veronica Clavijo Jordan; Nicholas J Rotile; Eman Akam; Smitha Krishnan; Gunisha Arora; Hema Krishnan; Hannah Slattery; Noah Warner; Nathaniel Mercaldo; Christian T Farrar; Jeremy Wellen; Robert Martinez; Franklin Schlerman; Kenneth K Tanabe; Bryan C Fuchs; Peter Caravan
Journal:  Radiology       Date:  2020-04-28       Impact factor: 11.105

6.  Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Zobair M Younossi; Rohit Loomba; Mary E Rinella; Elisabetta Bugianesi; Giulio Marchesini; Brent A Neuschwander-Tetri; Lawrence Serfaty; Francesco Negro; Stephen H Caldwell; Vlad Ratziu; Kathleen E Corey; Scott L Friedman; Manal F Abdelmalek; Stephen A Harrison; Arun J Sanyal; Joel E Lavine; Philippe Mathurin; Michael R Charlton; Naga P Chalasani; Quentin M Anstee; Kris V Kowdley; Jacob George; Zachary D Goodman; Keith Lindor
Journal:  Hepatology       Date:  2018-07       Impact factor: 17.425

Review 7.  Molecular prognostic prediction in liver cirrhosis.

Authors:  Nicolas Goossens; Shigeki Nakagawa; Yujin Hoshida
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

8.  Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.

Authors:  Lynda Aoudjehane; Pierre-Yves Boelle; Grégoire Bisch; Rolland Delelo; François Paye; Olivier Scatton; Chantal Housset; Jérôme Becquart; Yvon Calmus; Filomena Conti
Journal:  Lab Invest       Date:  2016-03-07       Impact factor: 5.662

Review 9.  Non-invasive assessment of liver fibrosis in patients with alcoholic liver disease.

Authors:  Rosa Lombardi; Elena Buzzetti; Davide Roccarina; Emmanuel A Tsochatzis
Journal:  World J Gastroenterol       Date:  2015-10-21       Impact factor: 5.742

Review 10.  Fibrosis assessment: impact on current management of chronic liver disease and application of quantitative invasive tools.

Authors:  Yan Wang; Jin-Lin Hou
Journal:  Hepatol Int       Date:  2016-01-07       Impact factor: 6.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.